Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:JANXNASDAQ:TARSNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$23.45-2.5%$21.28$16.50▼$26.50$2.04BN/A66,889 shs2,374 shsJANXJanux Therapeutics$23.51-7.2%$29.06$22.52▼$71.71$1.39B3.24858,039 shs252,814 shsTARSTarsus Pharmaceuticals$40.85-1.5%$48.21$20.08▼$57.28$1.72B0.94693,233 shs314,789 shsUPBUpstream Bio$8.54-1.3%$8.06$5.14▼$29.46$461.02MN/A325,577 shs81,832 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.66%-6.31%+28.56%+34.68%+2,403,999,900.00%JANXJanux Therapeutics-2.80%-0.96%-12.05%-31.13%-49.33%TARSTarsus Pharmaceuticals-6.20%-10.74%-10.70%-20.77%+8.05%UPBUpstream Bio-8.95%+5.36%+17.37%+20.81%+864,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AJANXJanux Therapeutics2.326 of 5 stars3.50.00.00.04.13.30.0TARSTarsus Pharmaceuticals3.0568 of 5 stars4.50.00.00.03.52.50.6UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AJANXJanux Therapeutics 3.09Buy$95.25305.15% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.3362.39% UpsideUPBUpstream Bio 3.00Buy$56.50561.59% UpsideCurrent Analyst Ratings BreakdownLatest UPB, JANX, TARS, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/6/2025TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $58.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.002/28/2025JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $76.002/26/2025TARSTarsus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$62.00 ➝ $60.002/26/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $73.002/24/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $78.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.08N/AN/AN/A∞JANXJanux Therapeutics$10.59M131.38N/AN/A$7.46 per share3.15TARSTarsus Pharmaceuticals$233.67M7.34N/AN/A$5.95 per share6.87UPBUpstream Bio$2.30M200.09N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AJANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%N/ATARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%5/14/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest UPB, JANX, TARS, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/A2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AJANXJanux TherapeuticsN/A38.8038.80TARSTarsus Pharmaceuticals0.305.425.38UPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AJANXJanux Therapeutics75.39%TARSTarsus Pharmaceuticals90.01%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AJANXJanux Therapeutics8.10%TARSTarsus Pharmaceuticals8.25%UPBUpstream BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AJANXJanux Therapeutics3059.17 million37.05 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableUPBUpstream Bio3853.79 millionN/AN/AUPB, JANX, TARS, and AAPG HeadlinesRecent News About These CompaniesBalyasny Asset Management L.P. Invests $4.95 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 13 at 5:14 AM | marketbeat.comEnavate Sciences GP LLC Acquires Shares of 2,459,703 Upstream Bio, Inc. (NASDAQ:UPB)May 11 at 8:04 AM | marketbeat.comQ2 EPS Estimates for Upstream Bio Decreased by William BlairMay 10, 2025 | marketbeat.comDeep Track Capital LP Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Invests $1.40 Million in Upstream Bio, Inc. (NASDAQ:UPB)May 9, 2025 | marketbeat.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comUpstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial PositionMay 6, 2025 | tipranks.comUpstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsMay 6, 2025 | globenewswire.comSamsara BioCapital LLC Acquires Shares of 2,217,146 Upstream Bio, Inc. (NASDAQ:UPB)May 2, 2025 | marketbeat.comSoros Fund Management LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)May 2, 2025 | marketbeat.comTCG Crossover Management LLC Takes $44.86 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)May 1, 2025 | marketbeat.comNantahala Capital Management LLC Acquires Shares of 600,000 Upstream Bio, Inc. (NASDAQ:UPB)April 30, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB)April 30, 2025 | marketbeat.comLynx1 Capital Management LP Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 29, 2025 | marketbeat.comDecheng Capital LLC Buys Shares of 3,285,293 Upstream Bio, Inc. (NASDAQ:UPB)April 28, 2025 | marketbeat.comGeode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 28, 2025 | marketbeat.comMarshall Wace LLP Makes New $4.78 Million Investment in Upstream Bio, Inc. (NASDAQ:UPB)April 27, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading 7.2% Higher - Here's What HappenedApril 23, 2025 | marketbeat.comBain Capital Life Sciences Investors LLC Acquires New Holdings in Upstream Bio, Inc. (NASDAQ:UPB)April 23, 2025 | marketbeat.comUpstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is ImminentApril 17, 2025 | seekingalpha.comFmr LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB)April 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryDatadog Earnings Delight: Q1 Strength and an Upbeat Forecast By Jeffrey Neal Johnson | May 9, 2025View Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast UPB, JANX, TARS, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$23.45 -0.59 (-2.45%) As of 10:19 AM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Janux Therapeutics NASDAQ:JANX$23.51 -1.82 (-7.19%) As of 10:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Tarsus Pharmaceuticals NASDAQ:TARS$40.85 -0.61 (-1.47%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Upstream Bio NASDAQ:UPB$8.54 -0.11 (-1.27%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
